| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CMTM4; CKLFSF4; CKLF-like MARVEL transmembrane domain-containing protein 4; Chemokine-like factor superfamily member 4 |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CKLF4. AA range:161-210 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets CMTM4 and detects endogenous levels of CMTM4 protein.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | CMTM4 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~25.8 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CKLF4. AA range:161-210 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 146223; Mouse: 97487 |
| UniProt | Q8IZR5 (Human: Q8IZR5; Mouse: Q8CJ61) |
Scientific Background
CMTM4 belongs to the chemokine-like factor gene superfamily, a novel family that is similar to the chemokine and the transmembrane 4 superfamilies of signaling molecules. CMTM4 is one of several chemokine-like factor genes located in a cluster on chromosome 16. Alternatively spliced transcript variants encoding different isoforms have been identified.
Alternative Names
CMTM4; CKLFSF4; CKLF-like MARVEL transmembrane domain-containing protein 4; Chemokine-like factor superfamily member 4
Safety & Handling
| Target | CMTM4 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~25.8 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CKLF4. AA range:161-210 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 146223; Mouse: 97487 |
| UniProt | Q8IZR5 (Human: Q8IZR5; Mouse: Q8CJ61) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
CMTM4 belongs to the chemokine-like factor gene superfamily, a novel family that is similar to the chemokine and the transmembrane 4 superfamilies of signaling molecules. CMTM4 is one of several chemokine-like factor genes located in a cluster on chromosome 16. Alternatively spliced transcript variants encoding different isoforms have been identified.
Alternative Names
CMTM4; CKLFSF4; CKLF-like MARVEL transmembrane domain-containing protein 4; Chemokine-like factor superfamily member 4
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
